Seres Therapeutics
Seres Therapeutics raises $113M Series E at $450M valuation
Seres Therapeutics: Series E Funding Round
Seres Therapeutics has successfully raised $113M in Series E funding, reaching a valuation of $450M.
Company Overview
Microbiome therapeutic platform
Funding Details
The Series E round was led by Flagship Pioneering, with participation from Polaris Partners, Fidelity, Nestle Health Science, Takeda Ventures.
Company Information
- Headquarters: 200 Sidney Street, Cambridge, MA 02139
- Founded: 2010
- Employees: 250+
- Category: Biotech
Investment
Seres Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Flagship Pioneering: Verified investor in Series E
- Polaris Partners: Verified investor in Series E
- Fidelity: Verified investor in Series E
- Nestle Health Science: Verified investor in Series E
- Takeda Ventures: Verified investor in Series E
Company Info
Investors (5)
Share
Related Reports
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free